Recent Quotes (30 days)

You have no recent quotes
chg | %

Vermillion, Inc.  

(Public, NASDAQ:VRML)   Watch this stock  
Find more results for VRML
2.04
+0.03 (1.49%)
Dec 15 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.98 - 2.05
52 week 0.91 - 2.85
Open 2.03
Vol / Avg. 35,565.00/95,057.00
Mkt cap 122.40M
P/E     -
Div/yield     -
EPS -0.21
Shares 60.00M
Beta 2.37
Inst. own 35%
Nov 8, 2017
Q3 2017 Vermillion Inc Earnings Call
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin -358.94% -566.54%
Operating margin -357.51% -566.01%
EBITD margin - -538.64%
Return on average assets -112.75% -103.30%
Return on average equity -264.97% -140.49%
Employees 33 -
CDP Score - -

Address

Suite 100 12117 Bee Caves Road Building Three
AUSTIN, TX 78738
United States - Map
+1-512-5190400 (Phone)
+1-512-4396980 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Vermillion, Inc. is a diagnostic service and bio-analytic solutions provider. The Company is engaged in the business of developing and commercializing diagnostic tests for gynecologic disease. It sells OVA1 risk of malignancy test for pelvic mass disease (OVA1). OVA1 is a blood test designed to, in addition to a physician's clinical assessment of a woman with a pelvic mass, identify women who are at risk of having a malignant ovarian tumor prior to planned surgery. It developed OVA1 through pre-clinical studies in collaboration with various academic medical centers encompassing over 2,500 clinical samples. OVA1 is validated in a multi-center clinical trial encompassing approximately 30 sites reflective of the diverse nature of the clinical centers, at which ovarian adnexal masses are evaluated. Its ASPiRA LABS is a laboratory that provides diagnostic services using a biomarker-based diagnostic algorithm to inform clinical decision making and personalized treatment plans.

Officers and directors

James T. LaFrance Chairman of the Board
Age: 58
Bio & Compensation  - Reuters
Valerie Barber Palmieri President, Chief Executive Officer
Age: 53
Bio & Compensation  - Reuters
Fred Ferrara Chief Operating Officer
Age: 49
Bio & Compensation  - Reuters
Donald G. Munroe Ph.D. Senior Vice President - Business Development, Chief Scientific Officer
Age: 58
Bio & Compensation  - Reuters
Eric J. Schoen Chief Accounting Officer, Vice President - Finance
Age: 46
Bio & Compensation  - Reuters
James S. Burns Independent Director
Age: 69
Bio & Compensation  - Reuters
Veronica G. H. Jordan Ph.D. Independent Director
Age: 64
Bio & Compensation  - Reuters
David R Schreiber Independent Director
Age: 55
Bio & Compensation  - Reuters
Carl Severinghaus Independent Director
Age: 63
Bio & Compensation  - Reuters
Eric K. Varma M.D. Independent Director
Age: 33
Bio & Compensation  - Reuters